文献速递脊柱关节炎

古塞奇尤单抗治疗活动性银屑病关节炎1年III期研究结果

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
PubMed 文献 · RMD Open · 2021-01-01

这项III期随机研究评估了古塞奇尤单抗(IL-23p19抑制剂)在活动性银屑病关节炎患者中1年的疗效与安全性,患者包括生物制剂初治或TNFα抑制剂经治者。结果显示,古塞奇尤单抗在52周内维持了ACR20/50/70、皮肤反应及疾病活动度改善,且无论既往是否使用TNFi均维持应答,安全性良好。

要点

  • 古塞奇尤单抗在52周内维持ACR20/50/70及皮肤应答。
  • TNFi初治和经治患者均维持对古塞奇尤单抗的应答。
  • 至60周安全性良好,未发现新的安全信号。

核心结论

  • 古塞奇尤单抗在52周内持续改善银屑病关节炎的多项临床表现,并维持良好的获益-风险特征,无论既往是否暴露于TNFi。

研究设计与样本

  • III期随机研究,纳入符合ClASsification criteria for Psoriatic ARthritis且疾病活动(≥3个肿胀关节和≥3个压痛关节;C反应蛋白≥0.3 mg/dL)的成人患者。
  • 患者随机(1:1:1)接受古塞奇尤单抗100 mg每4周、古塞奇尤单抗100 mg第0/4周后每8周、或安慰剂并在第24周交叉至古塞奇尤单抗100 mg每4周,至第48周。
  • 31%的患者既往接受过≤2种TNF抑制剂;共381例治疗患者,90%完成研究。

主要发现

  • 第24周后观察到ACR20应答比例数值增加,至第52周时Q4W随机组达73%(94/128),Q8W随机组达60%(76/127)。
  • 古塞奇尤单抗随机组至第52周维持了ACR50/ACR70、皮肤应答及最小/极低疾病活动度的比例,并维持身体功能和健康相关生活质量的改善。
  • TNFi初治和经治患者均维持对古塞奇尤单抗的应答。
  • 至第60周,古塞奇尤单抗Q4W随机组严重不良事件和严重感染发生率分别为3%和0%,Q8W随机组分别为6%和2%,与第24周观察相比无新的安全问题。
  • 无古塞奇尤单抗治疗患者死亡,安慰剂组有2例死亡;无机会性感染或炎症性肠病发生。

关键数值与推荐

  • ACR20应答:第52周Q4W随机组73%(94/128),Q8W随机组60%(76/127)。
  • 严重不良事件:至第60周Q4W随机组3%,Q8W随机组6%。
  • 严重感染:至第60周Q4W随机组0%,Q8W随机组2%。

临床怎么用

  • 古塞奇尤单抗可作为活动性银屑病关节炎患者的治疗选择,无论其既往是否使用过TNF抑制剂。
  • 治疗1年内应持续评估疗效,关注ACR应答及皮肤、功能和生活质量改善的维持。
  • 至60周的安全性数据支持其耐受性良好,无需因新安全信号调整监测策略。

局限性

  • 未报告安慰剂对照阶段之后的盲态维持情况;非应答者插补法可能影响应答率估计。
  • 样本量有限,长期安全性数据仍需扩展研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year. METHODS: Adults who met ClASsification criteria for Psoriatic ARthritis, with active disease (≥3 swollen and ≥3 tender joints; C reactive protein ≥0.3 mg/dL) despite standard treatment (31% previously received ≤2 tumour necrosis factor inhibitors (TNFi)), were randomised (1:1:1) to guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at Week0, Week4, then Q8W; or placebo with cross-over to guselkumab 100 mg Q4W at Week24 (PBO→Q4W) through Week48. Clinical efficacy through Week52 (employing non-responder imputation) and adverse events (AEs) through Week60 were evaluated. RESULTS: Of 381 treated patients, 90% completed the study. Numerical increases in the proportions of patients achieving ≥20% improvement in ACR criteria (ACR20) were observed post-Week24, reaching 73% (94/128) and 60% (76/127) for Q4W-randomised and Q8W-randomised patients, respectively, by Week52. Proportions of patients achieving ACR50/ACR70/skin responses and minimal/very low disease activity were maintained, as were improvements in physical function and health-related quality of life, through Week52 in guselkumab-randomised patients. Response to guselkumab was maintained in both TNFi-naïve and TNFi-experienced patients. Serious AEs and serious infections occurred in similar proportions of guselkumab Q4W-randomised (3% and 0%) and Q8W-randomised (6% and 2%) patients through Week60, with no new safety concerns versus observations through Week24. No guselkumab-treated patient and two patients receiving placebo died; no study participant developed opportunistic infection or inflammatory bowel disease. CONCLUSION: Guselkumab provided sustained improvement across multiple clinical manifestations of PsA, maintaining a favourable benefit-risk profile, through 1 year regardless of prior TNFi exposure.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. RMD Open. 2021. PMID: 33568556. doi:10.1136/rmdopen-2020-001457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。